Pregnancy Clinical Trial
Official title:
The Maternal Lifestyle Study
This is a longitudinal, multi-site observational study of the long-term effects of a mother's use of cocaine and/or opiates during pregnancy on her infant. This observational study evaluates the medical, developmental, social, environmental, and neurobehavioral outcomes for 1,400 of the original cohort of children. A series of follow-up examinations of these children were conducted in 5 phases: 1-36 months, 3.5-7 years, and 8-11 years. Children are currently being examined at 13 years of age.
Interest in and availability of cocaine, marijuana, and opiates have complicated long-term
investigations into the effects of the widespread recreational use of easily accessible
substances like alcohol and tobacco. It remains impossible to determine in single site,
small number studies what effects may be related to the use of a specific drug. By accessing
the large multi-site population of newborn infants and their mothers available in the NICHD
Neonatal Research Network, this study is evaluating the short- and long-term effects of
mothers' cocaine and/or opiate use during pregnancy on their term or preterm infants.
Maternal practices assessed in this study include the use and abuse of opiates, cocaine,
alcohol, marijuana, and nicotine. This study will address acute perinatal events and
long-term medical, developmental, social, environmental, and neurobehavioral outcomes of
infants whose mothers engaged in these maternal practices. The study will determine whether
specific acute and long-term effects can be attributed to the use and abuse of specific
substances.
Over 2 years, approximately 20,000 infants were screened with a goal of enrolling 16,000
infants. It was estimated that approximately 20% of infants would have been exposed to
cocaine or opiates. The determination of exposure was based on self-report by the mother or
positive meconium assay.
The first phase of the study evaluated the acute effects of maternal practices on infants.
This phase involved all mothers who agreed to respond to the initial questionnaire and who
allowed the meconium drug screen to be performed on their infants. Acute outcomes are being
compared between infants who were exposed to cocaine and opiates through their mothers' use
(the exposed group) and infants who were not exposed (the nonexposed group). Acute outcomes
include abruptio placenta, fetal growth retardation, non-life threatening congenital
malformations, respiratory distress syndrome, chronic lung disease,
periventricular-intraventricular hemorrhage, necrotizing enterocolitis, retinopathy of
prematurity, and periventricular leukomalacia.
The second phase of the study compared 1,400 exposed and nonexposed infants with respect to
long-term neurodevelopmental outcomes. These infants were among the 16,000 infants enrolled
in Phase I. It was estimated that 70% of the screened population would consent to
participate in Phase II of the study, and 50% of these participants would complete all
visits over the initial 3-year study period (2,000 exposed infants enrolled into Phase II
and 1,000 exposed infants would complete all follow-up visits). For each exposed infant, an
infant of similar age, race, sex, and either alcohol history or maternal age was selected
from the nonexposed, screened population. All infants had physical, neurological,
gestational age, and growth assessments at birth. The exposed and nonexposed infants were
examined at 1, 4, 7, 9, 12, 18, 24, and 36 months corrected age. Follow-up assessments
include medical history, and developmental, behavioral, social, and environmental outcomes.
The third phase of the study compared children at ages 4 to 7. The fourth phase is now
comparing outcomes in children ages 8 to 11 years old. Assessments include measures of
cognition, school performance, antisocial behavior, onset of substance use, psychopathology,
neuroendocrine function, and health disorders. Seventy-one percent of the original sample is
still enrolled.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Completed |
NCT02520687 -
Effects of Dietary Nitrate in Hypertensive Pregnant Women
|
Phase 1 |